ToolGen Incorporated Share Price

Equities

A199800

KR7199800004

Biotechnology & Medical Research

End-of-day quote Korea S.E. 23:00:00 28/05/2024 BST 5-day change 1st Jan Change
62,300 KRW -4.15% Intraday chart for ToolGen Incorporated +1.30% -11.25%

Financials

Sales 2022 743M 540K 42.49M Sales 2023 1.1B 802K 63.06M Capitalization 556B 404M 31.76B
Net income 2022 -18.18B -13.21M -1.04B Net income 2023 -42.34B -30.78M -2.42B EV / Sales 2022 511 x
Net cash position 2022 52.68B 38.3M 3.01B Net cash position 2023 4.22B 3.07M 241M EV / Sales 2023 500 x
P/E ratio 2022
-23.7 x
P/E ratio 2023
-13.1 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 76.76%
More Fundamentals * Assessed data
Dynamic Chart
ToolGen Incorporated announced that it has received KRW 33 billion in funding CI
ToolGen Incorporated announced that it expects to receive KRW 33 billion in funding CI
Toolgen Leads Development of Numerous Cutting-Edge Genome Editing Techniques CI
ToolGen Incorporated Reports Earnings Results for the Full Year Ended December 31, 2022 CI
ToolGen Incorporated(KOSDAQ:A199800) added to S&P Global BMI Index CI
MCureX Therapeutics, Inc. Signs Contract for Joint Research with Toolgen, Inc CI
ToolGen Incorporated has completed an IPO in the amount of KRW 70 billion. CI
ToolGen Incorporated has filed an IPO. CI
ToolGen Incorporated announced that it has received KRW 10.0000004 billion in funding from Genexine, Inc. CI
ToolGen Incorporated announced that it expects to receive KRW 10.0000004 billion in funding from Genexine, Inc. CI
Genexine, Inc. cancelled the acquisition of ToolGen Incorporated. CI
Genexine, Inc. agreed to acquire ToolGen Incorporated for approximately KRW 350 billion. CI
ToolGen, Inc., Demonstrates CRISPR/Cas9 Gene Editing Improves Anti-Tumor Activity of Human Car-T Cells CI
Monsanto Company and ToolGen, Inc. Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers CI
ToolGen, Inc. Highlights Study Results Demonstrating Utility of AAV-Compatible Cas9 System in vivo Genome Editing CI
More news
1 day-4.15%
1 week+1.30%
Current month-8.65%
1 month-5.61%
3 months+25.48%
6 months-20.23%
Current year-11.25%
More quotes
1 week
62 300.00
Extreme 62300
72 000.00
1 month
59 200.00
Extreme 59200
87 600.00
Current year
45 550.00
Extreme 45550
110 000.00
1 year
26 100.00
Extreme 26100
110 000.00
3 years
26 100.00
Extreme 26100
166 500.00
5 years
22 100.00
Extreme 22100
166 500.00
10 years
22 100.00
Extreme 22100
173 700.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 -
Chief Executive Officer 56 03/09/19
Chief Tech/Sci/R&D Officer 48 -
Members of the board TitleAgeSince
Director/Board Member 57 -
Director/Board Member 65 -
Chief Executive Officer 56 03/09/19
More insiders
Date Price Change Volume
29/05/24 62,300 -4.15% 40,503
28/05/24 65,000 +0.31% 21,303
27/05/24 64,800 +0.31% 37,194
24/05/24 64,600 +6.95% 256,592
23/05/24 60,400 -1.79% 21,362

End-of-day quote Korea S.E., May 28, 2024

More quotes
ToolGen, Inc. is principally engaged in the development of engineered nucleases. The Company’s main products portfolio consists of ribose nucleic acid (RNA)-guided endonucleases (RGEN) as well as deoxyribonucleic acid (DNA)-directed RGEN (dRGEN), which are applied as tools for editing genetic information in microbial, plant, animal and human cells. In addition, it is involved in the provision of genome engineering services.
More about the company
  1. Stock Market
  2. Equities
  3. A199800 Stock